COTI-2 demonstrates activity against many common p53 gene mutations
Critical Outcome Technologies Inc. (TSX Venture: COT) (“COTI” or the “Corporation”) announces positive results from experiments carried out with its lead cancer drug candidate, COTI-2, in the cancer research laboratories of Gordon Mills, M.D., Ph.D. Chair of the Department of Systems Biology and the Co-director of the Khalifa Institute for Personalized Cancer Therapy at The…